Evotec SE (EVO) Cash from Investing Activities (2009 - 2026)
Evotec SE (EVO) posted Cash from Investing Activities of -$14557.1 for Q1 2026, down 100.01% sequentially from $199.8 million in Q4 2025, and up 35.95% YoY from -$10707.6 in Q1 2025.
Evotec SE (EVO) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Evotec SE has reported Cash from Investing Activities for 9 years, with the latest figure at -$14557.1 in Q1 2026.
- Quarterly Cash from Investing Activities rose 35.95% year-over-year to -$14557.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $199.8 million (up 362.62% YoY) and the FY2025 annual result came in at $199.7 million, up 362.57% from the prior year.
- Cash from Investing Activities retreated to -$14557.1 in Q1 2026 per EVO's latest filing, from $199.8 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $199.8 million in Q4 2025 and troughed at -$420.7 million in Q4 2022.
- A 5-year average of -$18.3 million and a median of -$28464.8 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities slumped 191439.37% in 2022, then jumped 362.98% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$420.7 million in 2022, then jumped by 96.6% to -$14.3 million in 2023, then plunged by 430.62% to -$76.0 million in 2024, then surged by 362.98% to $199.8 million in 2025, then plunged by 100.01% to -$14557.1 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$14557.1, $199.8 million, and -$8465.1 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Evotec SE | 687.23 Mn | 686.75 Mn | - | -14,557.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,557.05 |
| Mar 31, 2026 | -14,557.05 |
| Dec 31, 2025 | 199.80 Mn |
| Dec 31, 2025 | 199.80 Mn |
| Sep 30, 2025 | -8,465.13 |
| Sep 30, 2025 | -8,465.13 |
| Jun 30, 2025 | -24,838.59 |
| Jun 30, 2025 | -24,838.59 |
| Mar 31, 2025 | -22,728.07 |
| Mar 31, 2025 | -22,728.07 |
| Dec 31, 2024 | -75.98 Mn |
| Dec 31, 2024 | -75.98 Mn |
| Sep 30, 2024 | -28,464.75 |
| Sep 30, 2024 | -28,464.75 |
| Jun 30, 2024 | -33,687.20 |
| Jun 30, 2024 | -33,687.20 |
| Mar 31, 2024 | -33,576.18 |
| Mar 31, 2024 | -33,576.18 |
| Dec 31, 2023 | -14.32 Mn |
| Dec 31, 2023 | -14.32 Mn |